Press Releases

Sedana Medical AB (publ) announces that the company has received a positive decision from the authorities in all involved countries that the pediatric indication of Sedaconda (isoflurane) is approvable in Europe. This marks the final step before 14 European...

Sedana Medical AB (publ) has today completed the acquisition of Innovatif Cekal, the supplier of the company’s main product (Sedaconda ACD). The acquisition will enable better control of the supply chain and improved profitability by reducing the...

According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the Annual General Meeting 2025 shall be composed of members appointed by the three largest shareholders, along with...

Raising our 2024 sales guidance and integrating our European trial into the US submission - strengthening our file, but extending timelines Third quarter 2024 January-September 2024 CEO comments With a strong focus on our top three priorities - driving...

According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the Annual General Meeting 2025 shall be composed of members appointed by the three largest shareholders as of September...

Sedana Medical AB (publ) plans to present its interim report for the third quarter of 2024 on Thursday October 24 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the third quarter 2024 on Thursday...

Second quarter 2024 January-June 2024 CEO comments We continue to focus on our ambitious goals for 2024: achieving an all-time-high in sales, reaching EBITDA break-even outside of the US during the year, and progressing towards our single biggest growth...

“I am excited about acquiring Innovatif Cekal as this transaction is a perfect fit with our strategy. After streamlining our non-customer-facing functions and implementing a vigorous shift of resources towards the frontline, this strategic move...

According to the financial calendar, Sedana Medical plans to publish the interim report for the second quarter 2024 on Tuesday July 23 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the...

“The completion of INSPiRE-ICU 2 concludes Sedana Medical´s clinical trials in the United States. Running this study together with esteemed clinical investigators from highly ranked academic centers such as Columbia, the Harvard-affiliated...